share_log

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Price Target Cut to €57.95

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Price Target Cut to €57.95

Fresenius Medical Care AG&Co.KGaA(紐約證券交易所市場代碼：FMS)目標價下調至57.95歐元
Defense World ·  2022/08/12 05:21

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) had its price target cut by research analysts at Berenberg Bank from €76.70 ($78.27) to €57.95 ($59.13) in a research report issued to clients and investors on Wednesday, The Fly reports.

Fresenius Medical Care AG&Co.KGaA(紐約證券交易所代碼：FMS-GET評級)在週三發佈給客户和投資者的一份研究報告中，貝倫貝格銀行的研究分析師將其目標價從76.70歐元(78.27美元)下調至57.95歐元(59.13美元)。

Several other brokerages have also recently issued reports on FMS. Truist Financial reduced their target price on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a "hold" rating for the company in a report on Wednesday, June 22nd. StockNews.com cut shares of Fresenius Medical Care AG & Co. KGaA from a "strong-buy" rating to a "buy" rating in a report on Friday, July 15th. Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from an "underperform" rating to a "buy" rating and raised their target price for the stock from $30.30 to $33.70 in a report on Monday, June 27th. UBS Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "neutral" rating in a research report on Friday, July 29th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a research report on Monday, August 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $45.83.

其他幾家券商最近也發佈了關於FMS的報告。Truist Financial在6月22日週三的一份報告中將Fresenius Medical Care AG&Co.KGaA的目標價從34.00美元下調至27.00美元，並將該公司的評級設定為持有。在7月15日星期五的一份報告中，StockNews.com將Fresenius Medical Care AG&Co.KGaA的股票評級從“強勢買入”下調至“買入”。在6月27日週一的一份報告中，傑富瑞金融集團將費森尤斯醫療保健股份公司的股票評級從表現不佳上調至買入，並將該股的目標價從30.30美元上調至33.70美元。在7月29日星期五的一份研究報告中，瑞銀集團將費森尤斯醫療保健股份公司的股票評級從買入下調至中性。最後，摩根大通在8月1日週一的一份研究報告中將費森尤斯醫療保健公司KGaA的目標股價從51.00歐元(合52.04美元)下調至23.00歐元(合23.47美元)。一名分析師對該股的評級為賣出，七名分析師給出了持有評級，四名分析師對該公司給予了買入評級。根據MarketBeat.com的數據，該公司目前的平均評級為持有，平均目標價為45.83美元。

Get
到達
Fresenius Medical Care AG & Co. KGaA
費森尤斯醫療保健股份公司
alerts:
警報：

Fresenius Medical Care AG & Co. KGaA Trading Up 0.5 %

費森尤斯醫療保健股份公司KGaA股價上漲0.5%。

NYSE FMS opened at $18.85 on Wednesday. The company has a fifty day simple moving average of $23.68 and a two-hundred day simple moving average of $29.31. The stock has a market cap of $11.05 billion, a P/E ratio of 12.02, a P/E/G ratio of 0.92 and a beta of 1.02. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $18.16 and a 12-month high of $40.85. The company has a current ratio of 1.18, a quick ratio of 0.85 and a debt-to-equity ratio of 0.47.

紐約證交所FMS週三開盤報18.85美元。該公司的50日簡單移動均線切入位23.68美元，200日簡單移動均線切入位29.31美元。該股市值為110.5億美元，市盈率為12.02，市盈率為0.92，貝塔係數為1.02。費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)的股價為18.16美元，為12個月低點，12個月高位為40.85美元。該公司的流動比率為1.18，速動比率為0.85，債務權益比率為0.47。

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

對衝基金買入費森尤斯醫療保健股份公司KGaA

A number of institutional investors and hedge funds have recently bought and sold shares of FMS. Pzena Investment Management LLC boosted its position in Fresenius Medical Care AG & Co. KGaA by 47.6% during the fourth quarter. Pzena Investment Management LLC now owns 9,459,446 shares of the company's stock worth $307,054,000 after acquiring an additional 3,051,672 shares during the last quarter. First Trust Advisors LP raised its stake in Fresenius Medical Care AG & Co. KGaA by 15.1% during the fourth quarter. First Trust Advisors LP now owns 1,925,326 shares of the company's stock worth $62,496,000 after purchasing an additional 252,768 shares during the period. Bank of America Corp DE raised its stake in Fresenius Medical Care AG & Co. KGaA by 27.9% during the first quarter. Bank of America Corp DE now owns 1,083,689 shares of the company's stock worth $36,499,000 after purchasing an additional 236,459 shares during the period. Cambiar Investors LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 18.3% during the first quarter. Cambiar Investors LLC now owns 1,363,874 shares of the company's stock worth $45,935,000 after purchasing an additional 210,819 shares during the period. Finally, Invesco Ltd. raised its stake in Fresenius Medical Care AG & Co. KGaA by 54.0% during the fourth quarter. Invesco Ltd. now owns 376,173 shares of the company's stock worth $12,211,000 after purchasing an additional 131,870 shares during the period. 4.73% of the stock is currently owned by institutional investors and hedge funds.
一些機構投資者和對衝基金最近買賣了FMS的股票。Pzena Investment Management LLC第四季度將其在費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)的頭寸增加了47.6%。Pzena Investment Management LLC在上個季度額外收購了3,051,672股後，現在擁有9,459,446股該公司股票，價值307,054,000美元。First Trust Advisors LP第四季度將其在費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)的持股增加了15.1%。First Trust Advisors LP現在擁有1,925,326股該公司的股票，價值62,496,000美元，在此期間又購買了252,768股。美國銀行第一季度將其在Fresenius Medical Care AG&Co.KGaA的持股比例提高了27.9%。美國銀行DE目前持有1,083,689股該公司股票，價值36,499,000美元，在此期間又購買了236,459股。Cambiar Investors LLC在第一季度增持了費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)18.3%的股份。Cambiar Investors LLC現在擁有1,363,874股該公司的股票，價值45,935,000美元，在此期間又購買了210,819股。最後，景順在第四季度將其在Fresenius Medical Care AG&Co.KGaA的持股比例提高了54.0%。景順股份有限公司目前持有376,173股該公司股票，價值12,211,000美元，在此期間又購買了131,870股。4.73%的股票目前由機構投資者和對衝基金持有。

Fresenius Medical Care AG & Co. KGaA Company Profile

費森尤斯醫療保健股份公司簡介

(Get Rating)

(獲取評級)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Fresenius Medical Care AG&Co KGaA在德國、北美和國際上提供透析護理和相關的透析護理服務。它通過門診透析診所網絡提供透析治療以及相關的實驗室和診斷服務；材料、培訓和患者支持服務，包括臨牀監測、後續援助和安排將用品運送到患者住所；以及根據合同向美國醫院提供為住院的終末期腎病(ESRD)患者和急性腎功能衰竭患者提供的透析服務。

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on Fresenius Medical Care AG & Co. KGaA (FMS)
  • Look at Honeywell for a Steady and Diversified Stock
  • Why Invest in High-Yield Dividend Stocks?
  • Find and Profitably Trade Stocks at 52-Week Lows
  • Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
  • Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
  • 免費獲取StockNews.com關於Fresenius Medical Care AG&Co.KGaA(FMS)的研究報告。
  • 霍尼韋爾看好穩定和多元化的股票
  • 為什麼要投資高收益股利股票？
  • 找到並獲利於52周低點的股票交易
  • 迪士尼(NYSE：DIS)的股票剛剛給了投資者一個巨大的信號
  • 清潔能源法案通過後，太陽能股大放異彩

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

接受Fresenius Medical Care AG&Co.KGaA Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Fresenius Medical Care AG&Co.KGaA和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論